Investors in RGNX Have Chance to Take Action in REGENXBIO Inc. Securities Fraud Case

Investors who have purchased securities from REGENXBIO Inc. (RGNX) between February 9, 2022, and January 27, 2026, have been reminded by The Schall Law Firm, a reputable shareholder rights litigation firm, of an ongoing class action lawsuit against the company for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5 by the U.S. Securities and Exchange Commission.

Individuals who find themselves in this category are advised to get in touch with the firm by April 14, 2026, to explore their options. The complaint against REGENXBIO Inc. centers on claims that the company made deceptive statements that were misleading to investors. The specific focus is on a product candidate known as RGX-111, which was promoted positively to the market without disclosing detrimental data concerning its efficacy and safety. It was later revealed that a participant in the RGX-111 study developed an intraventricular CNS tumor. These alleged actions by REGENXBIO Inc. resulted in damages to investors when the actual facts were made known to the public.

For individuals who have suffered financial losses due to these circumstances, participating in the lawsuit may provide a chance to recover. The Schall Law Firm, which specializes in securities class action lawsuits and shareholder rights claims, is well-positioned to represent the interests of affected investors across the globe. The firm stands ready to engage with impacted parties free of charge, offering insights on their legal rights and the available recourse.

As with any legal case, it’s worth noting that the class action has not yet been certified, meaning that those who are part of the affected group are not presently represented by an attorney. By taking proactive steps and engaging with the situation, investors have the opportunity to become involved in the process rather than remaining passive observers.

This notification serves as an alert to shareholders who may have been impacted by the actions of REGENXBIO Inc. during the specified period. With the guidance and representation of The Schall Law Firm, investors have the potential to seek redress and hold the company accountable for its purported transgressions. Whether through participation in the pending lawsuit or pursuing individual legal remedies, affected parties are encouraged to take appropriate steps to protect their rights and interests.